Quantcast

For a better bladder: Axonics Modulation Technologies files for an $86 million IPO


Shutterstock photo

Axonics Modulation Technologies, which is commercializing a neural implant for overactive bladder and incontinence, filed on Friday with the SEC to raise up to $86 million in an initial public offering.

The Irvine, CA-based company was founded in 2012 and booked $0.1 million in sales for the 12 months ended June 30, 2018. It plans to list on the Nasdaq under the symbol AXNX. Axonics Modulation Technologies filed confidentially on August 28, 2018. BofA Merrill Lynch and Morgan Stanley are the joint bookrunners on the deal. No pricing terms were disclosed.

The article For a better bladder: Axonics Modulation Technologies files for an $86 million IPO originally appeared on IPO investment manager Renaissance Capital's web site renaissancecapital.com.

Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital's Renaissance IPO ETF (symbol: IPO) , Renaissance International ETF (symbol: IPOS) , or separately managed institutional accounts may have investments in securities of companies mentioned.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs



More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs










Research Brokers before you trade

Want to trade FX?